What are the recommendations for patients with clinical ASCVD who are receiving maximally tolerated statin therapy and whose LDL-C level is 70 mg/dL or higher (1.8 mmol/L)?
In patients with clinical ASCVD who are receiving maximally tolerated statin therapy and whose LDL-C level remains 70 mg/dL or higher (1.8 mmol/L), it may be reasonable to add ezetimibe. This recommendation is unchanged from 2018 Cholesterol Guidelines. For high-intensity statin therapy, the 2018 ACC/AHA Cholesterol Guidelines recommend atorvastatin 80 mg daily or rosuvastatin 20 mg daily. Please refer to these guidelines for contraindications to high-intensity statin therapy and recommendations for moderate-intensity statin therapy.